Seeking Alpha

Alexion (ALXN +1.8%) bounces back today after slipping despite a strong earnings report...

Alexion (ALXN +1.8%) bounces back today after slipping despite a strong earnings report yesterday. Jefferies ups its price target from $68 to $76 on the shares, saying that sales of its marquee drug Soliris were higher than expected. Canaccord agrees, noting that the stock is a solid earnings execution story.
Comments (4)
  • CLEMENT BLUM
    , contributor
    Comments (3) | Send Message
     
    I AM AN INDIVIDUAL RETIRED INVESTOR IN HOUSTON.
    25 Apr 2012, 10:55 PM Reply Like
  • CLEMENT BLUM
    , contributor
    Comments (3) | Send Message
     
    WHY WOULD SOMEONE SET THE PRICE TARGET ON THE STOCK AT $76 WHEN THE STOCK IS TRADING AT AROUND $88 NOW?
    C. J. BLUM
    25 Apr 2012, 10:59 PM Reply Like
  • Jason Aycock
    , contributor
    Comments (104) | Send Message
     
    Because their analyst isn't bullish on the stock ... they switched from Buy to Hold late 2010, and they set price targets below the trading price more than a year ago.

     

    They did raise the target on valuation, but it seems like other firms like Canaccord are much more bullish with aggressive targets.
    25 Apr 2012, 11:24 PM Reply Like
  • CLEMENT BLUM
    , contributor
    Comments (3) | Send Message
     
    ALXN IS TRADING AROUND $88 PER SHARE. THE ARTICLES QUOTED ABOVE ARE ERRONEOUS
    25 Apr 2012, 10:59 PM Reply Like
DJIA (DIA) S&P 500 (SPY)